|1.||Lanari, Claudia: 12 articles (03/2012 - 05/2002)|
|2.||Hyder, Salman M: 9 articles (01/2015 - 10/2007)|
|3.||Besch-Williford, Cynthia: 7 articles (01/2015 - 10/2007)|
|4.||Bonny, Andrea E: 6 articles (10/2015 - 04/2004)|
|5.||Curtis, Kathryn M: 6 articles (05/2013 - 06/2002)|
|6.||Molinolo, Alfredo A: 6 articles (01/2012 - 05/2003)|
|7.||Hendrix, Susan L: 6 articles (02/2009 - 06/2003)|
|8.||Stefanick, Marcia L: 6 articles (02/2009 - 12/2002)|
|9.||Langer, Robert D: 6 articles (06/2008 - 11/2002)|
|10.||Lin, Feng: 6 articles (02/2006 - 12/2002)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/1998 - "We herein report the case of a patient with recurrent breast cancer who showed a remarkable improvement in her quality of life (QOL) as a result of a good response to medroxyprogesterone acetate (MPA). "
01/01/1998 - "Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care."
08/01/2000 - "Treatment of advanced or recurrent breast cancer with medroxyprogesterone acetate (MPA) shows high response rates and the accessory effects of appetite stimulation, improvement in performance status (PS) and bone marrow protection. "
12/01/1987 - "Low dose oral medroxyprogesterone acetate is as effective as high dose therapy in the treatment of advanced breast cancer, and is cheaper and less toxic."
10/31/1979 - "(MPA) Medroxyprogesterone acetate when employed at high doses (5001000 mg/day intramuscularly) can produce objective remission with improved survival in about 30% of postmenopausal women with advanced breast cancer resistant to cytotoxic drugs and endocrine therapies. "
09/01/1988 - "In summary, oral medroxyprogesterone acetate is effective in relieving symptoms and objectively improving endometriosis. "
03/01/1976 - "Efficacy of oral medroxyprogesterone acetate (MPA) was assessed in 35 women with an established diagnosis of endometriosis (33 pelvic and 2 abdominal). "
07/01/2000 - "To determine the efficacy of medroxyprogesterone acetate (MPA), 50 mg/d for 3 months, in treating endometriosis, with a follow-up of 6 months. "
03/01/2000 - "The efficacy of depot medroxyprogesterone acetate in the treatment of endometriosis was assessed in 19 patients with severe diseases. "
10/01/2015 - "Primary cultures of stromal cells from healthy endometrium (E-IUM) or endometriomas (E-OSIS) were subjected to in vitro decidualization (IVD) using 1 μM medroxyprogesterone acetate, 35 nM 17β-estradiol, and 0.05 mM 8-Br-cAMP. "
05/01/1996 - "A study on the activity and tolerability of high-dose medroxyprogesterone acetate in the treatment of ACS in neoplastic patients was carried out in a series of 103 patients with advanced cancer beyond cure with standard chemotherapeutic or radiotherapeutic treatments. "
10/01/1986 - "All 101 patients who simultaneously had ERC and PRC in concentrations higher than 30 fmol/mg protein remained disease free for 2 years, whereas all recurrences in patients with receptor-poor tumors appeared during the 2 years of medroxyprogesterone acetate treatment. "
04/01/2006 - "Medroxyprogesterone acetate (200 mg/day) was effective in one RCT, particularly in patients with well-differentiated, receptor-positive tumors. "
02/01/1998 - "Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial."
05/20/1989 - "At the doses used in this study, however, no inhibitory effect on tumor growth or synergism between medroxyprogesterone acetate and CDDP was observed. "
10/01/2004 - "Following a period of 6 months after the initiation of Depo Provera, 30% became amenorrhoeic, 70% noticed improvement in their bleeding pattern and 15% had an increase in their haemoglobin levels. "
10/01/2014 - "Patients in Group 1 (126 patients) received 100 mg of CC daily for 5 days starting on day 5 of menses, and patients in Group 2 (126 patients) received 100 mg of CC daily for 5 days starting the next day after finishing medroxyprogesterone acetate (MPA) (before withdrawal bleeding). "
09/01/2012 - "She received a 2-month drug holiday every 4 to 6 months to allow for withdrawal menstrual bleeding with medroxyprogesterone acetate. "
10/01/2006 - "Cessation of bleeding had occurred in 88% of the OC group and 76% of those receiving medroxyprogesterone acetate, with a median time to bleeding cessation of 3 days for both groups. "
01/01/2006 - "Successful treatment of depot medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in adolescents."
|5.||Endometrial Neoplasms (Endometrial Cancer)
03/01/2015 - "The efficacy of fertility-sparing treatment with a high-dose of medroxyprogesterone acetate for grade 1 endometrial cancer was proven in a Japan clinical oncology group (JCOG) phase II study. "
10/01/2013 - "[Study of mechanism of medroxyprogesterone 17-acetate on the cancer stem cell-like properties of human endometrial cancer]."
06/01/1999 - "Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group."
12/01/1991 - "Based on a pilot study, an open, randomized, crossover trial has been performed on 22 breast and endometrial cancer patients to evaluate the relative bioavailability of this new oral formulation (200-mg sachet, twice daily) as compared with a standard formulation (Farlutal, 500-mg tablet, twice daily). "
04/01/1981 - " The study by McDaniel and Potts of women with endometrial cancer hospitalized in Chiang Mai and Lumpoon Provinces which examined Depo-Provera use among them had too small a sample to detect less than a 20-fold relative risk; moreover, very few cases of endometrial cancer actually came in for treatment. "
|1.||Medroxyprogesterone Acetate (Depo-Provera)
|5.||Conjugated (USP) Estrogens (Premarin)
|7.||Megestrol Acetate (Borea)
|8.||Gonadotropin-Releasing Hormone (GnRH)
|1.||Contraception (Birth Control)
|3.||Drug Therapy (Chemotherapy)
|4.||Estrogen Replacement Therapy